MIR548AH: A Potential Drug Target and Biomarker (G100616254)

Target Name: MIR548AH

NCBI ID: G100616254

MIR548AH

Other Name(s): hsa-miR-548ah-5p | microRNA 548ah | hsa-mir-548ah | MicroRNA 548ah | hsa-miR-548ah-3p

MIR548AH: A Potential Drug Target and Biomarker

MIR548AH, also known as interleukin-5 (IL-5), is a protein that is expressed in various tissues of the body, including the lungs, heart, kidneys, and intestines. It is a key regulator of inflammation and immune responses, and has been implicated in a number of diseases, including asthma, Chronic obstructive pulmonary disease (COPD), and autoimmune disorders. In this article, we will discuss the potential drug target and biomarker properties of MIR548AH, and the research being conducted to understand its role in human disease.

The MIR548AH protein is composed of 151 amino acids and has a calculated molecular weight of 19.9 kDa. It is expressed in a variety of tissues, including the lungs, heart, kidneys, and intestines, and is involved in the regulation of inflammation and immune responses. MIR548AH is a key regulator of the production of pro-inflammatory cytokines, such as IL-12 and IL-13, which are involved in the recruitment of immune cells to the site of inflammation and the initiation of an inflammatory response.

One of the unique features of MIR548AH is its ability to interact with several different signaling pathways, including the TGF-β pathway and the NF-kappa-B pathway. The TGF-β pathway is involved in the regulation of cell growth and differentiation, and is a well-established target for many drugs, including anti-inflammatory drugs. The NF-kappa-B pathway is involved in the regulation of inflammation and immune responses, and is also a potential target for many drugs. MIR548AH has been shown to interact with both the TGF-β and NF-kappa-B pathways, suggesting that it may be a useful drug target for the treatment of a variety of diseases.

In addition to its potential drug target properties, MIR548AH has also been shown to be a potential biomarker for a number of diseases. For example, MIR548AH has been shown to be elevated in the blood samples of individuals with severe asthma, a group of individuals characterized by persistent and severe symptoms of asthma that require frequent use of bronchodilators. In addition, MIR548AH has been shown to be elevated in the blood samples of individuals with COPD, a progressive lung disease that is characterized by persistent coughing and shortness of breath. These findings suggest that MIR548AH may be a useful biomarker for the diagnosis and treatment of COPD.

In conclusion, MIR548AH is a protein that is involved in the regulation of inflammation and immune responses. Its unique ability to interact with multiple signaling pathways makes it a potential drug target for the treatment of a variety of diseases. In addition, MIR548AH has also been shown to be a potential biomarker for the diagnosis and treatment of COPD. Further research is needed to fully understand the role of MIR548AH in human disease and to develop effective treatments.

Protein Name: MicroRNA 548ah

The "MIR548AH Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about MIR548AH comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets